PTGS2 and colorectal carcinoma: This pathway controls the expression of cyclooxygenase-2 (COX-2), which is often upregulated in aggressive CRC and linked to a weaker response to 5-FU [185] and cisplatin due to the induction of MDR1 and MRP1 expression [186].